Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : 4D Molecular Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
4DMT And Arbor Partner To Co-Develop Next-Gen Genetic Medicines For CNS Diseases
Details : 4DMT and Arbor will co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates for central nervous system diseases, including amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : 4D Molecular Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership